Table 2 Evaluation of antibody responses at different time points.

From: Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host

Day

CLIA (AU/mL)

ELNA (titre)

Blot IgG (AU/mL)

Activity (U/mL)

RAI (%)

102

Positive (17.7)

Borderline (1:4)

Negative

1.28

n.d.

124

Positive (1320.0)

Positive (1:32)

Positive S1 (209), RBD (405)

106.7

2.9

182

Positive (>2080.0)

Positive (>1:32)

Positive S1 (294), RBD (459)

145.5

17.4

250

Positive (1750.0)

Positive (1:32)

Positive S1 (229), RBD (353), S2 (85)

69.1.

22.9

  1. Overview of the patient's serological data from day 102, 124 and 182. The used diagnostic tools were the LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin S.p.A., Saluggia, Italy) (LIAISON), an Immunoblot called ViraChip assay (Viramed, Munich, Germany), Avidity and an in-house Enzyme-Linked Neutralization Assay (ELNA)56. The data obtained from LIAISON SARS-CoV-2 s1/s2 IgG CLIA assay are standardized according to the WHO criteria.
  2. CLIA chemoluminescent immunoassay, AU/mL arbitrary units/mL, ELNA enzyme-linked immunosorbent assay, S1 spike 1, RBD receptor-binding-domain, RAI relative avidity index formula: IgG concentration with chaotropic agent/IgG concentration with PBS.
Back to article page